Steba France

Steba Biotech is a clinical-stage biotechnology company focused on developing minimally invasive photodynamic therapies for various types of cancer. The company's lead product, Tookad (padeliporfin), is a light-sensitive drug used in conjunction with a laser device to target and destroy tumor vasculature. This Vascular Targeted Photodynamic (VTP) platform is currently approved in the European Union for the treatment of low-risk prostate cancer. Steba Biotech is also exploring the application of VTP in other solid tumors, including kidney and bladder cancers, through ongoing clinical trials. The company maintains a strong collaborative relationship with the Weizmann Institute of Science, where its core technology originated.